Nucleic acid aptamers and their complimentary antidotes. Entering an era of antithrombotic pharmacobiologic therapy.

Published

Journal Article

The translation of fundamental science-based constructs to the preemptive identification and optimal management of individuals with or those at risk for thrombotic disorders of the cardiovascular system has taken a step closer to being realized with the development of molecular technologies that include nucleic acid aptamers and their complimentary oligonucleotide antidotes. Herein, we summarize our experience with factor IX and von Willebrand factor aptamers, and introduce the era of antithrombotic pharmacobiologic therapy.

Full Text

Pubmed Central version
Link to Item

Duke Authors

Becker, Richard Clinton
Sullenger, Bruce Alan

Cited Authors

Becker, RC; Oney, S; Becker, KCD; Rusconi, CP; Sullenger, B

Published Date

December 2007

Published In

Hamostaseologie

Volume / Issue

27 / 5

Start / End Page

378 - 382

PubMed ID

18060250

Pubmed Central ID

18060250

International Standard Serial Number (ISSN)

0720-9355

Language

Conference Location

Germany